Telix reports 63% revenue jump to $390m

Telix Pharmaceuticals reported H1 2025 revenue of $390.4 million, up 63% year-over-year, and reaffirmed full-year guidance of $770-800 million. The RLS acquisition contributed $79.0 million from third-party product sales.

Despite an operating loss of $2.3 million, the company maintained positive operating cash flow of $17.7 million while investing $81.6 million in R&D.